Results from the phase 2 RESONATE™-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

被引：0
|
作者：
Stilgenbauer, S. [1 ]
Jones, J. A. [2 ]
Coutre, S. E. [3 ]
Mato, A. R. [4 ]
Hillmen, P. [5 ]
Tam, C. [6 ]
Osterborg, A. [7 ]
Siddiqi, T. [8 ]
Thirman, M. J. [9 ]
Furman, R. R. [10 ]
Ilhan, O. [11 ]
Keating, M. [12 ]
Call, T. G. [13 ]
Brown, J. R. [14 ]
Stevens-Brogan, M. [15 ]
Li, Y. [15 ]
Clow, F. [15 ]
James, D. F. [15 ]
Chu, A. D. [15 ]
Hallek, M. [16 ,17 ]
O'Brien, S. [12 ]
机构：
[1] Univ Ulm, D-89069 Ulm, Germany
[2] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[3] Stanford Univ, Sch Med, Div Hematol, Stanford Canc Ctr, Stanford, CA 94305 USA
[4] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[5] Leeds Teaching Hosp, St James Inst Onco, Leeds, W Yorkshire, England
[6] Peter MacCallum Canc Ctr, East Melbourne, Australia
[7] Karolinska Univ Hosp Solna, Dept Hematol, Solna, Sweden
[8] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA
[9] Univ Chicago Med, Hematol Oncol Sect, Chicago, IL USA
[10] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA
[11] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey
[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[13] Mayo Clin, Div Hematol, Rochester, MN USA
[14] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA
[15] Pharmacyclics Inc, Sunnyvale, CA USA
[16] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[17] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V291
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Fardis, Maria
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [2] Results from the phase 2 RESONATE™-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion
    Munir, T.
    O'Brien, S.
    Jones, J. A.
    Coutre, S. E.
    Mato, A. R.
    Hillmen, P.
    Tam, C.
    Osterborg, A.
    Siddiqi, T.
    Thirman, M. J.
    Furman, R. R.
    Ilhan, O.
    Keating, M.
    Call, T. G.
    Brown, J. R.
    Stevens-Brogan, M.
    Li, Y.
    Clow, F.
    James, D.
    Chu, A.
    Hallek, M.
    Stilgenbauer, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 71 - 71
  • [3] Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial
    Byrd, John C.
    Brown, Jennifer R.
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Kay, Neil E.
    Reddy, Nishitha M.
    Coutre, Steven E.
    Tam, Constantine
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Devereux, Steve
    Barr, Paul M.
    Furman, Richard R.
    Kipps, Thomas J.
    Cymbalista, Florence
    Fardis, Maria
    McGreivy, Jesse S.
    Clow, Fong
    James, Danelle Frances
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [4] Randomized comparison of ibrutinib versus ofaturuumab to relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial
    Byrd, John C.
    Brown, Jennifer R.
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Kay, Neil E.
    Reddy, Nishitha M.
    Coutre, Steven E.
    Tam, Constantine
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Devereux, Steve
    Barr, Paul M.
    Furman, Richard R.
    Kipps, Thomas J.
    Cymbalista, Florence
    Fardis, Maria
    McGreivy, Jesse S.
    Clow, Fong
    James, Danelle Frances
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven E.
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael J.
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    LANCET ONCOLOGY, 2016, 17 (10): : 1409 - 1418
  • [6] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
  • [7] Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study
    Stilgenbauer, Stephan
    Jones, Jeffrey A.
    Coutre, Steven
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael
    Call, Timothy G.
    Brown, Jennifer R.
    Li, Yunfeng
    Eckert, Karl
    Chang, Betty Y.
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    O'Brien, Susan
    BLOOD, 2015, 126 (23)
  • [8] Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
    Hillmen, Peter
    Eichhorst, Barbara
    Brown, Jennifer R.
    Lamanna, Nicole
    O'Brien, Susan M.
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Grosicki, Sebastian
    Mital, Andrzej
    Robak, Tadeusz
    Osterborg, Anders
    Yimer, Habte A.
    Salmi, Tommi
    Ji, Meng
    Yecies, Jessica
    Idoine, Adam
    Wu, Kenneth
    Huang, Jane
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (05) : 1035 - +
  • [9] A DOSE ESCALATION STUDY OF IBRUTINIB WITH LENALIDOMIDE FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Pollyea, D.
    Gore, L.
    Gutman, J.
    Eckhardt, S. G.
    Hagelstrom, N.
    Coutre, S.
    Thirman, M.
    Byrd, J.
    ANNALS OF ONCOLOGY, 2013, 24 : 33 - 33
  • [10] A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Pollyea, Daniel A.
    Coutre, Steven
    Gore, Lia
    Adler, Nichole
    Harris, Pamela
    Phelps, Mitch A.
    Johnson, Amy J.
    Ling, YongHua
    Li, Hao
    Gutman, Jonathan A.
    Byrd, John C.
    BLOOD, 2014, 124 (21)
12345